This book is the proceedings of the Falk Symposium 158, on Intestinal Inflammation and Colorectal Cancer, held in March 2007. It covers the current understanding of inflammation-driven colon carcinogenesis, highlights the most relevant mechanisms and discusses measures to interfere with this process. This is a true translational topic which will attract both basic scientists and clinicians, specifically those who can make a difference in preventing this type of cancer.
Contents List of principal contributors List of chairpersons Preface SECTION I: EPIDEMIOLOGY OF THE VILLAIN.- 1 Colorectal cancer in patients with inflammatory bowel disease: influence of nutritional.- 2 Inflammatory bowel disease high-risk groups.- SECTION II: NOT ALL COLORECTAL CANCERS ARE THE SAME.- 3 Getting familiar with familial colon cancer.- 4 The adenomatous polyposis coli tumour-suppressor protein in normal gut tissue maintenance and cancer.- 5 Mismatch repair competency predicts 5-fluorouracil effectiveness on patient survival.- 6 Inflammatory bowel disease-related cancer - just the same as sporadic? - Pro.- 7 Differences between sporadic and colitis-associated colorectal cancer.- SECTION III: SCREENING AND SURVEILLANCE.- 8 Endoscopic guidelines for hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, inflammatory bowel disease and sporadic colorectal cancer.- 9 Which new techniques will replace classical surveillance?.- 10 How to deal with dysplasia and adenomatous polyps in inflammatory bowel disease.- SECTION IV: TAKING DYSPLASIA TO THE MOLECULAR LEVEL.- 11 Inflammation-driven carcinogenesis: the players.- 12 Cancer originating from bone marrow stems cells: can we extrapolate from gastritis to colitis?.- 13 Translating laboratory findings into clinics: of mice and man.- SECTION V: HOW CAN WE PREVENT?.- 14 Inner and outer environment.- 15 Can we prevent inflammatory bowel disease-related colorectal cancer with 5-aminosalicylic acid, azathioprine, or 6-mercaptopurine? The clinical evidence.- 16 How can we prevent colorectal cancer with ursodeoxycholic acid?.- SECTION VI: MOLECULAR ACTIONS OF 5-ASA - THE MAGIC BULLETT.- 17 5-Aminosalicylic acid and replication fidelity.- 18 New mechanisms of action of 5-aminosalicylic acid: PPAR-gamma: how it decreases inflammation and cancer.- 19 Mesalazine and the prevention of colorectal cancer in inflammatorybowel disease.- 20 Mesalazine and cell cycle progression.- 21 Chemopreventive role of mesalazine in inflammatory bowel disease-associated colorectal cancer: the role of DNA methylation.- 22 Molecular actions of 5-aminosalicylic acid: the magic bullet on epidermal growth factor receptor signalling.- SECTION VII: STATE-OF-THE-ART LECTURE.- 23 State-of-the Art-Lecture: Infection, inflammation and cancer - the future.- SECTION VIII: PROGRESSION OF CANCER THROUGH INFLAMMATORY MECHANISMS.- 24 An integrating concept of malignant progression in colorectal cancer.- 25 The balance between survival and apoptosis.- 26 The tumour microenvironment regulates components of the fucose biosynthesis pathways in colorectal cancer cells.- ndex
Number Of Pages:
- ID: 9781402068256
- Saver Delivery: Yes
- 1st Class Delivery: Yes
- Courier Delivery: Yes
- Store Delivery: Yes
Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly
© Copyright 2013 - 2016 WHSmith and its suppliers.
WHSmith High Street Limited Greenbridge Road, Swindon, Wiltshire, United Kingdom, SN3 3LD, VAT GB238 5548 36